BTIG Reiterates Buy on Protagonist Therapeutics, Maintains $41 Price Target
Portfolio Pulse from Benzinga Newsdesk
BTIG analyst Julian Harrison has reiterated a 'Buy' rating on Protagonist Therapeutics (NASDAQ:PTGX) and maintained a price target of $41.
July 03, 2023 | 4:11 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Protagonist Therapeutics has received a reiterated 'Buy' rating from BTIG, with a maintained price target of $41.
The reiterated 'Buy' rating and maintained price target by BTIG indicates a positive outlook for Protagonist Therapeutics. This could potentially lead to increased investor confidence and a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100